Autologous stem cell transplantation is considered the standard of care for multiple myeloma patients aged < 65 years with no relevant comorbidities. The addition of drugs acting both on bone marrow microenvironment and on neoplastic plasma cells has significantly increased the proportion of patients achieving a complete remission after induction therapy, and these results are mantained after high-dose melphalan, leading to a prolonged disease control. Studies are being carried out in order to evaluate whether short term consolidation or long-term maintenance therapy can result into disease eradication at the molecular level thus increasing also patients survival. The efficacy of these new drugs has raised the issue of deferring the transplant after achiving a second response upon relapse. Another controversial point is the optimal treatment strategy for high-risk patients, that do not benefit from autologous stem cell transplantation and for whom the efficacy of new drugs is still matter of debate.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3507530PMC
http://dx.doi.org/10.4084/MJHID.2012.069DOI Listing

Publication Analysis

Top Keywords

stem cell
12
cell transplantation
12
multiple myeloma
8
autologous stem
8
efficacy drugs
8
update role
4
role autologous
4
autologous hematopoietic
4
hematopoietic stem
4
transplantation multiple
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!